Autoimmune Diseases  >>  Rebif (human IFN-β-1a)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
NCT00050778: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Checkmark AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Checkmark
Oct 2013 - Oct 2013: 
Checkmark CAMMS223
More
Completed
2
334
US, Europe, RoW
Interferon beta-1a, Rebif®, Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
09/07
01/10
NCT00489489 / 2006-003134-14: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed
2
118
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for Teriflunomide), Interferon-β, Avonex®, Rebif®, Betaseron®
Sanofi
Multiple Sclerosis
06/09
06/09
NCT00811395 / 2007-003997-24: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed
2
182
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for teriflunomide), Interferon-β [IFN-β], Avonex®, Rebif®, Betaseron®, Glatiramer Acetate [GA], Copaxone®
Sanofi
Multiple Sclerosis
04/10
04/10
RECYCLINE, NCT01134627 / 2005-004289-18: Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

Terminated
2
305
Europe
Minocycline, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
04/11
04/11
REPAIR, NCT01171209 / 2009-016824-29: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

Completed
2
10
Europe
Interferon-beta and human leukocyte Interferon-α, IFN-beta : Rebif, Betaferon, IFN-alfa: Multiferon®
Melinda Magyari, University of Copenhagen
Multiple Sclerosis
06/11
08/11
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12
NCT01404117: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Withdrawn
2
0
US
Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Multiple Sclerosis
12/13
01/14
CHOLINE, NCT01198132 / 2009-013695-46: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Completed
2
129
Europe
Cholecalciferol (Vitamin D3), Vitamin D3, Placebo, Rebif, Interferon beta-1a
Merck KGaA, Darmstadt, Germany, Merck Serono S.A.S, France
Multiple Sclerosis
03/15
11/15
SOLAR, NCT01285401 / 2010-020328-23: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Completed
2
260
Europe
VigantOL oil plus interferon beta-1a (Rebif), Placebo plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
04/15
05/15
EMR200136-549, NCT01514370: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Completed
2
80
Europe
IFN beta 1a 44 mcg TIW, Interferon beta 1a, Curcumin, Rebif, BCM95, Placebo
Merck KGaA, Darmstadt, Germany, Merck Serono S.P.A., Italy
Multiple Sclerosis
03/16
03/16

Download Options